Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
by on Monday, August 6th, 2012 | No Comments
Condition: Melanoma
Interventions: Drug: XL888; Drug: Vemurafenib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Exelixis
Recruiting – verified August 2012
Original post: Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma